Entities

EcoVadis provides sustainability intelligence for companies and their suppliers. Its ratings assess environmental practices, labour and human rights, ethics and sustainable procurement, producing scorecards and improvement plans that buyers can use in supplier selection and monitoring. Its platform also screens supply-chain risk, gathers carbon-emissions data and supports supplier decarbonisation, combining analyst assessments, documentation and AI-assisted data processing.

Develops rapid diagnostics that analyze the physical properties of immune cells in blood. Its IntelliSep test combines cell imaging, microfluidics and machine learning to help hospital clinicians assess sepsis risk and support earlier treatment decisions in emergency departments.

Develops implantable neuromodulation devices for chronic migraine. Its investigational system delivers targeted stimulation to nerves outside the skull, aiming to interrupt migraine-related signals. The company is conducting clinical studies to evaluate the system before seeking regulatory approval.

Route 92 Medical, Inc. is a privately held neurovascular medical-device company developing and commercializing catheter systems for endovascular treatment of acute ischemic stroke. Its Monopoint approach combines Tenzing delivery catheters with vessel-size-matched HiPoint and FreeClimb reperfusion or access catheters and Base Camp sheaths to simplify navigation and clot aspiration. Founded operationally in 2015 by physicians, it is headquartered in West Jordan, Utah, with a San Mateo presence; SEC filings name its earlier legal predecessor CBGB Medical. The FDA found the HiPoint Reperfusion System and Aspiration Tubing Set substantially equivalent under 510(k) K243601 on May 19, 2025, supporting its direct clot-aspiration indication. This device clearance is separate from earlier neurovascular-access clearances and trial IDE authorization. The company reported its first Canadian commercial procedures in June 2026 following a Health Canada Medical Device License. Its current public team includes ten executives and nine directors, with founder and CEO Tony Chou also board chair. Current issuer releases continue to describe it as privately held; acquisitions mentioned in directors’ biographies concern their earlier companies. Verified investors include InnovaHealth, Norwest, USVP, The Vertical Group, Novo Holdings and Sectoral. Its 2024 Series F extension is additional financing within the same Series F programme; the reported $82 million aggregate is not an additional cash raise.